Cargando…
Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921985/ https://www.ncbi.nlm.nih.gov/pubmed/24592333 http://dx.doi.org/10.1155/2014/762127 |
_version_ | 1782303388793307136 |
---|---|
author | Iasevoli, Felice Buonaguro, Elisabetta F. Marconi, Massimo Di Giovambattista, Emanuela Rapagnani, Maria Paola De Berardis, Domenico Martinotti, Giovanni Mazza, Monica Balletta, Raffaele Serroni, Nicola Di Giannantonio, Massimo de Bartolomeis, Andrea Valchera, Alessandro |
author_facet | Iasevoli, Felice Buonaguro, Elisabetta F. Marconi, Massimo Di Giovambattista, Emanuela Rapagnani, Maria Paola De Berardis, Domenico Martinotti, Giovanni Mazza, Monica Balletta, Raffaele Serroni, Nicola Di Giannantonio, Massimo de Bartolomeis, Andrea Valchera, Alessandro |
author_sort | Iasevoli, Felice |
collection | PubMed |
description | Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopathological features compared to those exposed to one antipsychotic (AP) and whether AP + AP patients showed significantly higher improvement compared to AP patients after a 4-week treatment. Methods. Inpatients were subdivided into AP + AP and AP ones. In the cross-sectional step, patients were compared according to demographics, clinical variables, and scores on rating scales. In the longitudinal step, patients remained for 4 weeks under admission medications and were compared for clinical improvement. Results. AP + AP patients were more frequently diagnosed with schizophrenia and mental retardation as a comorbid illness. AP + AP patients were more frequently under first-generation antipsychotics and had worse clinical presentation. After 4 weeks of treatment, both AP + AP and AP patients improved compared to the baseline. However, AP patients scored significantly less than AP + AP patients at the Clinical Global Impression Scale at the 4-week time point but not at the baseline, indicating a treatment-specific improvement. Conclusions. Antipsychotic polypharmacy may be offered to specific types of psychotic patients. However, efficacy of this strategy is limited at best. |
format | Online Article Text |
id | pubmed-3921985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39219852014-03-03 Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study Iasevoli, Felice Buonaguro, Elisabetta F. Marconi, Massimo Di Giovambattista, Emanuela Rapagnani, Maria Paola De Berardis, Domenico Martinotti, Giovanni Mazza, Monica Balletta, Raffaele Serroni, Nicola Di Giannantonio, Massimo de Bartolomeis, Andrea Valchera, Alessandro ISRN Pharmacol Clinical Study Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopathological features compared to those exposed to one antipsychotic (AP) and whether AP + AP patients showed significantly higher improvement compared to AP patients after a 4-week treatment. Methods. Inpatients were subdivided into AP + AP and AP ones. In the cross-sectional step, patients were compared according to demographics, clinical variables, and scores on rating scales. In the longitudinal step, patients remained for 4 weeks under admission medications and were compared for clinical improvement. Results. AP + AP patients were more frequently diagnosed with schizophrenia and mental retardation as a comorbid illness. AP + AP patients were more frequently under first-generation antipsychotics and had worse clinical presentation. After 4 weeks of treatment, both AP + AP and AP patients improved compared to the baseline. However, AP patients scored significantly less than AP + AP patients at the Clinical Global Impression Scale at the 4-week time point but not at the baseline, indicating a treatment-specific improvement. Conclusions. Antipsychotic polypharmacy may be offered to specific types of psychotic patients. However, efficacy of this strategy is limited at best. Hindawi Publishing Corporation 2014-01-27 /pmc/articles/PMC3921985/ /pubmed/24592333 http://dx.doi.org/10.1155/2014/762127 Text en Copyright © 2014 Felice Iasevoli et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Iasevoli, Felice Buonaguro, Elisabetta F. Marconi, Massimo Di Giovambattista, Emanuela Rapagnani, Maria Paola De Berardis, Domenico Martinotti, Giovanni Mazza, Monica Balletta, Raffaele Serroni, Nicola Di Giannantonio, Massimo de Bartolomeis, Andrea Valchera, Alessandro Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title | Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title_full | Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title_fullStr | Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title_full_unstemmed | Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title_short | Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study |
title_sort | efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921985/ https://www.ncbi.nlm.nih.gov/pubmed/24592333 http://dx.doi.org/10.1155/2014/762127 |
work_keys_str_mv | AT iasevolifelice efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT buonaguroelisabettaf efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT marconimassimo efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT digiovambattistaemanuela efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT rapagnanimariapaola efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT deberardisdomenico efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT martinottigiovanni efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT mazzamonica efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT ballettaraffaele efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT serroninicola efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT digiannantoniomassimo efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT debartolomeisandrea efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy AT valcheraalessandro efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy |